SPX3,911.74+116.01 3.06%
DIA315.02+8.28 2.70%
IXIC11,607.62+375.43 3.34%

BRIEF-GBT Presents Positive New Real-World Evidence Data Further Supporting Clinical Use Of Oxbryta In Sickle Cell Disease

reuters.com · 06/10/2022 03:09
BRIEF-GBT Presents Positive New Real-World Evidence Data Further Supporting Clinical Use Of Oxbryta In Sickle Cell Disease

- Global Blood Therapeutics Inc GBT:

  • GBT PRESENTS POSITIVE NEW REAL-WORLD EVIDENCE DATA AT EHA2022 CONGRESS FURTHER SUPPORTING CLINICAL USE OF OXBRYTA® (VOXELOTOR) IN SICKLE CELL DISEASE

  • GLOBAL BLOOD THERAPEUTICS- POSITIVE RESULTS FROM PHASE 1 STUDY OF GBT601, INCREMENTAL NEW DATA, SUPPORT ADVANCING INTO PHASE 2/3 TRIAL BY MID-YEAR

Source text for Eikon: ID:nGNX2qDcMx

Further company coverage: GBT


((Reuters.briefs@thomsonreuters.com;))